Cited 34 times since 2008 (2.1 per year) source: EuropePMC Current medical research and opinion, Volume 24, Issue 8, 17 3 2008, Pages 2151-2157 Prevention of sudden cardiac death: rationale and design of the Implantable Cardioverter Defibrillators in Dialysis patients (ICD2) Trial--a prospective pilot study. de Bie MK, Lekkerkerker JC, van Dam B, Gaasbeek A, van Buren M, Putter H, van Erven L, Bax JJ, Schalij MJ, Rabelink TJ, Jukema JW
Objective
Sudden cardiac (arrhythmic) death (SCD) is the single largest cause of death in dialysis patients. Prophylactic Implantable Cardioverter Defibrillator (ICD) therapy reduces SCD and reduces all-cause mortality in several groups of patients at high risk for arrhythmic death. Whether this also applies to dialysis patients is unknown.
Research design and methods
The Implantable Cardioverter Defibrillator in Dialysis patients (ICD2) trial is a prospective randomised controlled study. It has been designed to evaluate the efficacy and safety of prophylactic ICD therapy in reducing sudden cardiac death rates in dialysis patients aged 55-80 years. A total of 200 patients will be included. The primary endpoint of the study is sudden cardiac (arrhythmic) death. The mean follow-up time will be 4 years.
Trial registration
'The Netherlands Trial Register'--ISRCTN20479861
Conclusion
The ICD2 trial--a pilot study--will be the first study to evaluate the possible benefit of ICD therapy for the primary prevention of sudden cardiac death in dialysis patients.
